Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue

Trial Profile

Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Brimonidine/brinzolamide (Primary) ; Bimatoprost; Latanoprost; Travoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 15 Jan 2017 Planned End Date changed from 1 Feb 2017 to 22 Feb 2018.
    • 15 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 22 Feb 2018.
    • 26 Jul 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top